By InvitationEarly Phase 1

Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)

United States50 participantsStarted 2025-12-10

Plain-language summary

This laboratory-based study evaluates the effects of controlled cryogenic preservation on human cell samples using Truway Health's in-vitro cryo therapeutic methodology. The study analyzes post-thaw viability, functional recovery, and morphological integrity following exposure to different cryopreservation parameters. Findings will support optimization of cryogenic protocols intended for future translational, biobanking, and therapeutic applications.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * This study does not enroll human participants. Eligibility applies only to human-derived cell samples. * Samples must be de-identified prior to receipt. * Samples must demonstrate ≥90% viability at pre-freeze assessment. * Samples must be free of contamination (bacterial, fungal, mycoplasma). * Samples must meet chain-of-custody and biospecimen compliance requirements. Exclusion Criteria: * No human participants will be enrolled or contacted. * Any specimen containing identifiable private information. * Samples with inadequate quality, contamination, or compromised viability. * Samples obtained without appropriate donor consent or de-identification certification.

What they're measuring

Post-Thaw Viability

Timeframe: Twenty-four (24) hours after thaw

Trial details

NCT IDNCT07321028

SponsorTruway Health, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2066-12-10

View on ClinicalTrials.gov More Cellular Injury and Post-Cryogenic Recovery trials